End-of-day quote
Other stock markets
|
||
- EUR | - |
Apr. 22 | Pharming Group to Buy Back EUR123 Million of Bonds due 2025 | MT |
Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
Sales 2024 * | 262M 280M | Sales 2025 * | 300M 321M | Capitalization | 606M 648M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M | Net income 2025 * | 14M 14.97M | EV / Sales 2024 * | 1.97 x |
Net cash position 2024 * | 90.86M 97.15M | Net cash position 2025 * | 119M 128M | EV / Sales 2025 * | 1.62 x |
P/E ratio 2024 * |
-300
x | P/E ratio 2025 * |
40.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.66% |
Latest transcript on PHARMING GROUP
Managers | Title | Age | Since |
---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
Jeroen Wakkerman
DFI | Director of Finance/CFO | 55 | 20-11-15 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 20-12-10 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-05-18 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |